the european commission approved tecentriq in combination with avastin, paclitaxel and carboplatin for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (nsclc), including egfr mutant or alk-positive nsclc after failure of appropriate targeted therapies.
Answers
Answered by
1
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients withmetastatic non-squamous non-small cell lung cancer (NSCLC). ... Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapy before Receiving Recent Row.
Answered by
1
❤️ The european commission approved tecentriq in combination with avastin, paclitaxel and carboplatin for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (nsclc), including egfr mutant or alk-positive nsclc after failure of appropriate targeted therapies.
Similar questions